Skip to main content
ASPHO Logo
Menu Journal My Account Contact Join/Renew
Login
  • Meetings & Events
    • Conference
      • 2023 Conference
        • 2023 Conference
        • Hotel and Travel
        • Health and Safety
        • Registration
        • Schedule
        • Continuing Education
        • Corporate Symposia
        • Commercial Support
          • Virtual Exhibitor and Engagement Opportunities
        • Back to Meetings
      • Meetings Archive
      • Press | 2018 Conference
      • 2018 Call for Papers and Posters
        • Back to Meetings
        • 2019 Conference
        • Schedule of Events
        • Registration Rates
        • Conference Planning Committee
        • Conference Hotel and Travel
        • Faculty
        • 2019 Call for Papers and Posters
        • Continuing Education
        • PBMTC
        • Accepted Papers and Posters
        • Corporate Symposia
        • MOC Opportunities
        • App - Thank you for Attending
        • 2019 Attendee List
      • 2019 Call for Workshops
      • 2018 Conference
        • Schedule of Events
        • Accepted Papers and Posters
      • 2016 Annual Meeting
        • Overview
        • Attendee List
        • ASPHO Virtual Bag
        • Corporate Forum Symposia/Education Theaters
        • Accepted Papers and Posters
          • Accepted A-G
          • Accepted H-M
          • Accepted N-Z
          • 2016 Searchable Abstract Database
        • Exhibit Hall
        • Sponsors
        • Annual Meeting Brochure
        • 2017 Call for Workshops
        • Virtual Bag
        • Schedule of Events
        • Continuing Education
        • Attendee List
        • 2017 Searchable Abstract Database
        • Accepted Papers and Posters
        • Corporate Forum Symposia/Education Theater
        • Travel
        • Program Committee
        • Commercial Support
        • Exhibit with ASPHO
    • Review Course
      • 2023 Review Course
        • Review Course 2023 Cancellation Policies and Disclosures
      • Anderson 2019
      • McClain 2019
      • Adams 2019
      • Moran 2019
      • Effinger 2019
      • Fangusaro 2021
      • Brown 2021
      • Young 2021
      • Harker-Murray 2021
      • Effinger 2021
      • Pai 2021
      • Grace 2021
      • Rogers 2021
      • Anderson 2021
      • Powers 2021
      • McClain 2021
      • Neunert 2021
      • Fleming 2021
      • Mullen 2021
      • Pommert 2021
      • Meade 2021
      • Greengard 2021
      • Fox 2021
      • Bercovitz 2021
      • Brock 2021
      • Adams 2021
      • Loh 2021
      • O'Brien 2021
      • Walterhouse 2021
      • Pulsipher 2021
      • Oberley 2021
      • Rodriguez-Galindo 2021
      • Kesselheim 2021
      • Frei-Jones 2021
      • Allen 2021
      • 2015 Online Review Course CME Certificates
      • 2019 Planning Committee
      • 2019 Schedule
      • 2019 Travel
      • 2019 Review Course Early Career
      • 2019 Review Course Directors
        • 2019 Review Course Faculty
      • Oberley 2019
      • O'Brien 2019
      • Pai 2019
      • Pulsipher 2019
      • Rodriguez-Galindo 2019
      • Rogers 2019
      • Walterhouse 2019
      • Young 2019
      • Park 2019
      • Malec 2019
      • Evaluations
      • Brown 2019
      • Allen 2019
      • Fangusaro 2019
      • Fleming 2019
      • Frei-Jones 2019
      • Grace 2019
      • Harker-Murray 2019
      • Heeney 2019
      • Kesselheim 2019
      • Loh 2019
      • Mascarenhas 2019
      • Neunert 2019
      • Fangusaro 2023
      • Adams 2023
      • Neunert 2023
      • Oberley 2023
      • Grace 2023
      • Effinger 2023
      • Nakano 2023
      • Brock 2023
      • Harker-Murray 2023
      • Meade 2023
      • Fleming 2023
      • Kesselheim
      • Kumar 2023
      • Anderson 2023
      • Malogolowkin 2023
      • Pommert 2023
      • Bercovitz 2023
      • Frei-Jones 2023
      • O'Brien 2023
      • Pai 2023
      • Young 2023
      • Fox 2023
      • Powers 2023
      • Pulsipher 2023
      • McClain 2023
      • Loh 2023
      • Greengard 2023
      • Frazier 2023
      • Brennan 2023
      • Walkovich 2023
      • Browning 2023
      • 2023 Faculty
        • Office Hours
        • Learning Objectives and CME
        • Faculty
        • Planning Committee
      • Mullen 2023
      • 2023 Schedule
      • 2023 Learning Objectives and CME
      • Review Course Archive
    • Events Calendar
  • Knowledge Center
    • Products
      • KARE Toolkit: Knowledge and Assessment Resources
        • CME for KARE
        • CME for RC On-Demand
        • CME for PHO Review Course On Demand
        • CME for KARE Plus
        • CME for KARE Plus Hematology
        • CME for KARE Plus Oncology
        • The KARE Toolkit - Index of Topics
      • Recordings
      • Webinars
      • ASPHOcast
      • 2020 Compensation Survey
    • Online Review Course
    • Pediatric Blood & Cancer
      • Access Journal
      • Online Access Instructions
    • ASPHO eNews
      • August 2015 Enews
      • June 2015 Enews
      • April 2015 Enews
      • February 2015 Enews
      • December 2014 Enews
      • October 2014 Enews
      • August 2014 Enews
      • June 2014 Enews
      • April 2014 Enews
      • February 2014 Enews
      • December 2013 Enews
      • October 2013 Enews
      • August 2013 Enews
      • June 2013 Enews
      • April 2013 Enews
      • February 2013 Enews
      • October 2014 Enews
      • October 2015 Enews
      • December 2015 Enews
      • February 2016 Enews
      • April 2016 Enews
      • June 2016 Enews
        • DSIG Student Registration
      • August 2016 Enews
      • October 2016 Enews
      • December 2016 Enews
      • February 2017 Enews
      • April 2017 Enews
      • June 2017 Enews
      • August 2017 Enews
      • October 2017 Enews
      • December 2017 Enews
      • February 2018 Enews
      • April 2018 Enews
      • June 2018 Enews
      • August 2018 eNews
      • October 2018 eNews
      • February 2019 eNews
      • Member Insights: eNews 2018 Highlights
      • April 2019 eNews
      • June 2019 eNews
      • August 2019 eNews
      • October 2019 eNews
      • December 2019 eNews
      • February 2020 eNews
      • April 2020 eNews
      • June 2020 eNews
      • August 2020 eNews
      • October 2020 eNews
      • December 2020 eNews
      • April 2021 eNews
      • June 2021 eNews
      • August 2021 eNews
        • August 2021 President's Message
      • December 2021 eNews
      • February 2022 eNews
      • April 2022 eNews
      • June 2022 eNews
      • August 2022 eNews
      • October 2022 eNews
      • December 2022 eNews
      • February 2023 eNews
    • Pediatric Blood & Cancer - Call for Applications for Deputy Editor
    • October 2015 Enews
    • Advocacy Sample
    • News Briefs
    • Health Policy & Advocacy
      • 2016 August Advocacy Brief
      • 2016 December Advocacy Brief
      • 2017 February Advocacy Brief
      • 2017 May Advocacy Brief
      • 2017 September Advocacy Brief
      • 2017 November Advocacy Brief
      • 2018 Advocacy Brief - March
      • Contact Your Members of Congress
      • 2018-Advocacy-Brief-June
      • 2018-Advocacy-Brief-September
      • Advocacy Brief December 2018
      • 2019 Advocacy Brief - March
      • March 2019 Advocacy Brief
      • June 2019 Advocacy Brief
      • September 2019 Advocacy Brief
      • March 2020 Advocacy Brief
      • June 2020 Advocacy Brief
      • September 2020 Advocacy Brief
      • December 2020 Advocacy Brief
      • June 2021 Advocacy Brief
      • September 2021 Advocacy Brief
      • March 2022 Advocacy Brief
      • June 2022 Advocacy Brief
      • September 2022 Advocacy Brief
    • 2017 Workforce Survey Report
    • Help Fund the STAT Act
    • Practice and Quality
      • Choosing Wisely®
      • Position Paper
      • Endorsements
      • ASPHO Endorsements member only
  • Career Development
    • Mentoring
      • Early Career Mentoring
    • Awards
      • Distinguished Career Award
      • Oski Memorial Lectureship
      • International Travel Awards
      • Arceci Innovation Award
      • Buchanan Lectureship
      • Young Investigator Award
      • Young Investigator Form
      • EC Travel Stipend Form
      • Early Career Travel Stipend
      • Advanced Practice Provider Award
      • Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
    • Career Center
    • Fellowship Resources
      • Post-PHO Fellowship Program Directory
      • Fellowship Program Directors' Resources
    • Certification
      • Continuing Medical Education
      • advocating for moc
      • ABP MOC Letter Nov 2015
      • ABP Hematology/Oncology Content Outline
    • 2019 ASPHO Award Recipients
    • Workforce
  • Membership
    • Who Belongs
    • Benefits
    • Join Us
    • Renew
    • Membership Application
    • Fellows Group Application
    • Member Community
    • Find a Member
    • Special Interest Groups
      • Adolescent and Young Adult SIG
      • Advanced Practice Provider SIG
      • Cancer Predisposition SIG
      • Clinical Immunology SIG
      • Diversity SIG
        • 2017 DSIG Travel Award
      • Global Hem Onc SIG
      • Hemoglobinopathy SIG
      • Hospitalist Medicine SIG
      • Informatics, Innovation and Entrepreneurship SIG
      • Integrative Pediatric Hematology/Oncology SIG
      • Palliative Care SIG
      • Physician Scientist SIG
      • Quality Improvement and Patient Safety SIG
      • Small Program SIG
      • Vascular Anomalies SIG
      • Clinical Immunology SIG Webinar
      • Well-Being SIG
    • Enriching the Future
      • ETF Donors
      • ETF FAQ
      • ETF Programs
      • ETF Award Recipients
      • Donate
    • Stay Connected with ASPHO
    • New Member
    • Trainee Membership Level
    • Strengthen Your Everyday Practice
  • About
    • Governance
      • 2017 Election Nominations
      • 2019 Board and Nominating Committee members
      • Board of Trustees
      • Leadership Development & Election Process
      • Nominating FAQs
      • Strategic Plan
        • Leadership Domain
        • Education Domain
        • Career Domain
        • Administration Domain
      • Volunteer Opportunities
        • Early Career Council
    • Policies
      • Advertising Sponsorship
      • Support of CME
      • Committee Policies, Responsibilities, and Resources
      • Conflict of Interest and Disclosure for Volunteers
      • Distinguished Career Award Eligibility Criteria
      • Diversity Statement
      • Investment
      • Member Mailing List
      • Oski Eligibility Criteria
      • Presidential Stipend
      • Records Retention
      • Reserve Fund
      • Reviews and Endorsements
      • Speaker Reimbursement
      • Surveying Members
      • Whistleblower
      • Workshop Session
      • Young Investigator Award
      • Early Career Travel Stipend
      • Buchanan Lectureship Eligibility
      • ASPHO Statements
    • Terms of Use
    • Contact Us
    • 2016 Election Nominations
    • 2015 Election Candidates
    • FDA Approves Dinutuximab
    • Q&A Amy Billett
    • Fund Raising Policy
    • Support and Advertising
      • Exhibit
      • Advertising
      • Industry Relations Council
      • Grants
    • Diversity & Inclusion
    • Donate
  • 2017 Annual Meeting Session Recordings
  • 2018 Annual Meeting Session Recordings
  • George R. Buchanan Lectureship Award Presentation
  • Cancer Predispositions in Clinical Practice
  • Evidence and Equipoise in Pediatric Thrombosis - Updates from Randomized Controlled Trials
  • Playing on Our Strengths - Developing Interprofessional Teams in Pediatric Hematology-Oncology
  • Providing Optimal Pediatric Palliative Care: Overcoming the Barriers
  • When in Quebec, Do What the Quebecers Do (Part Deux) - It's All About Platelets!
  • Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Pediatric Patients with ALL in the era of Tyrosine Kinase Inhibitors, Novel Immunotherapies and 'MRD Status'
  • Award Presentations
  • Hemophilic Arthropathy, More Than Meets the Eye: Advances in Early Disease Detection from Clinical Tools to Musculoskeletal Imaging
  • ZFNs, CrispR/Cas9 and TALENS- Oh My!
  • Collaboration in the Treatment of Liver Tumors
  • Leukemia
  • Solid Tumors/Lymphoma
  • Hematology I
  • Beyond Antibodies and CAR T Cells: Challenges and Opportunities in Manipulating the Pediatric Cancer Immunome
  • Blood Clots in Sick Kids: A critical mini-review of venous thrombo-embolism in selected high-risk pediatric populations
  • It's not just about Diversity: Improving the Outcomes for All by Moving toward Equity
  • Children's Oncology Group (COG)
  • Outcomes Research
  • Social Media: The Good, The Bad, and Beyond
  • Sickle Cell Disease in the AYA population: Management Challenges for the Pediatric Hematologist
  • Molecularly Defined Rare Pediatric Sarcomas: An Update for the General Oncologist
  • Mechanisms of Tumor Microenvironment Immune Mediated Resistance and Methods of Therapeutic Circumvention
  • Behind the Scenes at Pediatric Blood & Cancer: Everything You Always Wanted to Know About Getting Published
  • New Insights in Inherited Hematologic Diseases
  • Changing Workforce of Pediatric Hematology/Oncology
  • New Diagnostic and Therapeutic Approaches of Opportunistic (Viral/Fungal) Infections in the Pediatric Cancer Patient
  • New Mutations and Targeted Therapies in Langerhans Cell Histiocytosis
  • Physician, Sustain Thyself: Building Resilience to Prevent Burnout
  • Practicing Precision in Pediatric Oncology: Three Perspectives
  • What's Happening in DC? A Look at ASPHO Advocacy Efforts
  • Critical Care of the Immunocompromised Pediatric Hematology/Oncology Patient
  • Brain Tumors
  • Hematology II
  • Sponsor, Exhibit, and Advertise
    • Exhibits
    • Advertising
    • Industry Relations Council
    • Exhibits Adveritising
  • Ward Testing OSE
  • 2018 Session | George R. Buchanan Lectureship Award Presentation
  • 2018 Session | Plenary Paper Session 2001-2002
  • 2018 Session | St. Baldrick's Foundation Robert J. Arceci Innovation Award Announcement
  • 2018 Session | Plenary Session—Health Care in the Current Political Climate: Stormy Days Ahead?
  • 2018 Session | Pediatric Ependymoma: The Science Driving Patient Care
  • 2018 Session | Iron: Let's Get Pumped
  • 2018 Session | Extracellular Vesicle Trafficking—Biology and Translational Impact in Hematology and Cancer
  • 2018 Session | Relapsed, Refractory, Metastatic Bone Sarcomas: New Insights on Pathogenesis, Prognosis and Treatment
  • 2018 Session | Alpha Thalassemia—A Growing Public Health Disease with Changing Landscape of In-Utero and Post-Natal Therapy
  • 2018 Session | Decision Making in Benign Hematology: Living in a World Without Randomized Trials
  • 2018 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
  • 2018 Session | Early Career Travel Stipend Awards
  • 2018 Session | Young Investigator Award Presentations
  • 2018 Session | Management of Extracranial Germ Cell Tumors in Adolescent and Young Adult Population
  • 2018 Session | Challenging Hematologic Complications Post–Stem Cell Transplantation and Beyond
  • 2018 Session | Advanced Symptom Management and End-of-Life Care: Multidisciplinary Primary Palliative Care for Pediatric Hematologists/Oncologists
  • 2018 Session | Paper Session - Solid Tumor
  • 2018 Session | Paper Session - Hematology
  • 2018 Session | Vascular Anomalies: The Great Mimickers
  • 2018 Session | Addressing Sexual Health in Adolescent and Young Adult Patients: What You Should Know as a Pediatric Hematology/Oncology Care Provider
  • 2018 Session | Navigating Intravascular Bottlenecks: A Critical Mini-Review of Pediatric Venous Thromboembolism in the Setting of an Anatomical Thrombophilia
  • 2018 Session | Paper Session - Children's Oncology Group (COG)
  • 2018 Session | Paper Session - Hematology Science
  • 2018 Session | Can Late Effects be Prevented in Pediatric Oncology?
  • 2018 Session | Clash of the Titans: Debates on Best Management of Patients with Bleeding Disorders
  • 2018 Session | Providing Effective Feedback: The Currency of Conflict Resolution
  • 2018 Session | Recent Advances and New Approaches to Rare Hematological Malignancies
  • 2018 Session | Primary and Secondary Stroke Prevention in Sickle Cell Disease: The Debate
  • 2018 Session | Combating an Unmet Need: Psychosocial Health
  • 2018 Session | Renal Tumors Beyond Wilms
  • 2018 Session | Pediatric and Neonatal Transfusion Medicine
  • 2018 Session | Mobile Applications in Clinical Practice
  • 2018 Session | Presidential Symposium—Partnering with Patients and Families to Improve Research and Clinical Decision-making
  • 2018 Session | Review of Rare Pediatric Head and Neck Tumors for the General Oncologist
  • 2018 Session | Emerging Therapies in Hemophilia
  • 2018 Session | How Should You Treat That Bug? A Debate About Antimicrobial Management in Fever and Neutropenia
  • 2018 Session | Paper Session with Luminary Investigator - Leukemia
  • 2018 Session | Paper Session with Luminary Investigator - Hematology
  • 2018 Session | Frank A. Oski Memorial Lectureship Award Presentation
  • December 2018 eNews
  • 2019 Session | Splenectomy - The Great Debate
  • 2019 Session | DICER1: Updates on Biology and Clinical Management
  • 2019 Session | Burnout in Pediatric Hematology/Oncology: Moving from Discussion to Action
  • 2019 Session | Diagnostic and Management Conundrums Surrounding Women with Heavy Menstrual Bleeding and Underlying Bleeding Disorders
  • 2019 Session | All That Glitters is Not Gold – How We Differentiate Primary HLH from Fake News
  • Models for International Pediatric Oncology Outreach
  • 2019 Session | Navigating Genetic Testing in the Pediatric Hematology Setting
  • 2019 Session | Radiation Therapy for Pediatric Cancer Patients: Updates and New Modalities
  • 2019 Session | The Microbiome: What Is It and Why Do We Care?
  • 2019 Session | Brain Attack: Therapeutic Advances in Neonatal and Childhood Stroke
  • 2019 Session | Advances in Pediatric AML
  • 2019 Session | Improving Medication Adherence for Adolescents and Young Adults: Is Technology the Answer?
  • 2019 Session | Metabolism in Pediatric Hematology/Oncology - Presidential Symposium
  • 2019 Session | Too Much of a Good Thing – Myeloproliferation in Children
  • 2019 Session | Multiple Bony Lytic Lesions, but Not Langerhans Cell Histiocytosis (LCH) – Now What?
  • 2019 Session | Savior Siblings: Medical, Ethical, and Psychosocial Considerations in using Preimplantation Genetic Diagnosis (PGD) to Ensure a Matched Sibling Donor for Hematopoietic Stem Cell Transplantation (HSCT)
  • 2019 Session | George R. Buchanan Lectureship Award Presentation
  • 2019 Session | 2019 St. Baldrick’s Foundation Robert J. Arceci Innovation Award Announcement and Past Recipient Presentation
  • 2019 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship Announcement and Frank A. Oski Memorial Lectureship Award Presentation
  • 2019 Session | New Paradigms for Severe Aplastic Anemia: Genetic Screening, Eltrombopag, and Up Front Unrelated Donor BMT
  • 2019 Session | Not Too Young for That Cancer: Adolescent and Young Adult Carcinomas
  • 2019 Session | Transforming the Treatment of Chronic Pain
  • 2019 Session | Putting an End to End Organ Damage in Sickle Cell Disease
  • 2019 Session | Defining Pediatric MDS: A Morphologic or Molecular Diagnosis?
  • 2019 Session | The Power of One: Present Challenges in Treating Rare Diseases
  • 2019 Session | Hematological Manifestations of Immune Deficiencies and Dysregulatory Disorders: When should you look harder for underlying causes of Autoimmune Cytopenias?
  • 2019 Session | Oncofertility Programs: More Than Just Sperm Banking
  • 2019 Session | The (Financial) Cost of a "Cure"
  • 2019 Session | (2001) Potential Utility of MRD to Identify Relapse in pALL Patients Treated with Tisagenlecleucel
  • 2019 Session | (2002) Lentiglobin Gene Therapy in Transfusion-Dependent Β-Thalassemia Patients with Non-β0/β0 Genotypes
  • 2019 Session | (2003) Mechanisms of Resistance to the Type II JAK2 Inhibitor CHZ868 in B-Cell Acute Lymphoblastic Leukemia
  • 2019 Session | (2004) Discovering Noncoding Genetic Elements that Regulate Globin Synthesis
  • 2019 Session | (2005) Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Safety & Efficacy
  • 2019 Session | (2006) Modeling IKZF1 Lesions in B-cell Acute Lymphoblastic Leukemia Reveals Potential Therapeutic Targets
  • 2019 Session | (2007) Prognostic Determinants in Childhood T-cell Acute Lymphoblastic leukemia: Results of DFCI 05001
  • 2019 Session | (2008) Gap Junction Interference increases Apoptosis in ALL cells and augments effects of Antimetabolites
  • 2019 Session | (2009) Hydroxyurea Lowers Tricuspid Regurgitant Jet Velocity in Children with Sickle Cell Anemia
  • 2019 Session | (2010) Novel Next-Generation Sequence based Assay for Non-Invasive Prenatal Testing of Sickle Cell Disease
  • 2019 Session | (2011) Gabapentin for Pain in Sickle Cell Disease: Results of a Randomized Phase II Clinical Trial
  • 2019 Session | (2012) Quality of Life is the most important Indication for Second-Line ITP Treatment in Children
  • 2019 Session | (2013) BCL2-Inhibitor Response in Neuroblastoma: Biomarkers and Therapy Resistance
  • 2019 Session | (2014) The Clinical Application of Molecular Testing in Pediatric Solid Tumors: An Institutional Experience
  • 2019 Session | (2015) Enhancing Tumor Directed T Cells with an Interleukin-7 Signal Modulator
  • 2019 Session | (2016) Epigenome Screening Identifies Transcriptional Elongation as Therapeutic Vulnerability in DIPG
  • 2019 Session | (2017) Levofloxacin Prophylaxis
  • 2019 Session | (2018) Renal Tumors: Future Roadmap
  • 2019 Session | (2019) Soft Tissue Sarcoma
  • 2019 Session | (2020) Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa
  • 2019 Session | (2021) Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia
  • 2019 Session | (2022) A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
  • 2019 Session | (2023) Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children
  • 2019 Session | The Role of Survivorship Research in Advancing Childhood Cancer Care and Quality of Survival
  • 2019 Session | (2024) Septic Shock (SS) Incidence in National ALL & AML Cohorts using Administrative & Clinical Trial Data
  • 2019 Session | (2025) Nelarabine Abrogates Relapse Rates in CNS-3 T-ALL: A Report from Children’s Oncology Group AALL0434
  • 2019 Session | (2026) Current Cancer Survivorship Practices: A Report from the Children’s Oncology Group (COG)
  • 2019 Session | (2027) Intra-Arterial Chemotherapy for Retinoblastoma: A 7-year Single Institution Experience
  • 2019 Session | Advancing Discovery in Hematology: Bench to Bedside? No. Bedside to Bench to Bedside...
  • 2019 Session | (2028) The Shwachman Diamond Syndrome Registry: Hematologic Complications
  • 2019 Session | (2029) Characteristics and Outcomes of Unprovoked Venous Thromboembolism in the Pediatric Population
  • 2019 Session | (2030) Third Party VST are an effective Therapy for the Treatment of BK-Virus Reactivation after Transplant
  • 2019 Session | (2031) Inhibition of Nemo-Like Kinase improves Erythropoiesis in Models of Diamond Blackfan Anemia
  • 2019 Annual Meeting Session Recordings
  • CI SIG Webinar
  • October 2021 eNews

ASPHO16 Advocacy web 

September 2018

The ASPHO Advocacy Brief

Welcome to the Advocacy Brief, a quarterly offering from the American Society of Pediatric Hematology/Oncology. The goal of this e-newsletter is to inform members about legislative and regulatory issues impacting the profession of pediatric hematology/oncology and the patients we serve.

*Send your health policy and advocacy news to  This email address is being protected from spambots. You need JavaScript enabled to view it.

ASPHO Bill Tracker

Visit ASPHO’s Legislative Tracking Chart to see a list of bills that ASPHO is monitoring.

Sickle Cell Awareness Month

September is Sickle Cell Awareness Month. September’s Advocacy Brief will bring a special focus to sickle cell disease and ASPHO’s efforts to advocate for sickle cell patients.

Special Feature

All Physicians Should Be Aware Of These Sickle Cell Issues 

As sickle cell disease is one of the most common serious conditions identified via newborn screening in the United States, all pediatricians should be familiar with sickle cell disease and aspects of its management. Feel free to share this list with practitioners in your community. 

  1. Penicillin prophylaxis: Start all newborns with sickle cell disease (newborn screen FS, FSA, or FSC) on penicillin 125 mg BID (dose increases to 250 mg BID at age 3 years). Encourage adherence and provide refills if necessary. Hematologists usually advise that most children can safely stop penicillin after age 5 years. A recent study using Medicaid claims data from five states unfortunately found that only 18% of children under age 5 years with sickle cell disease received ≥300 days of prophylactic antibiotics.1
  2. Fever: Always treat fever as an emergency in a child with sickle cell disease. All children with sickle cell disease with fever require an urgent medical evaluation that typically includes: CBC and reticulocyte count, blood culture, and an IV/IM antibiotic (usually ceftriaxone). Make sure all families know that they should not just monitor a child with fever at home.
  3. Pneumococcal immunizations: Children with sickle cell disease are at increased risk for pneumococcal sepsis due to functional asplenia. Immunize all children against pneumococcus with both the conjugate (Prevnar) and polysaccharide (Pneumovax) pneumococcal vaccines. If a child received Prevnar-7 as an infant, give a Prevnar-13 booster.
  4. TCD Screen for Stroke: Children with genotypes hemoglobin SS or Sβ0 thalassemia should receive an annual transcranial Doppler (TCD) ultrasound to identify children at increased risk for stroke. Help make sure these children get their TCD every year from age 2 to 16 years. Sadly many at-risk children do not receive an annual TCD.2,3
  5. Hydroxyurea: Hydroxyurea is a safe, well tolerated disease modifying medication for sickle cell disease (in particular for hemoglobin SS and Sβ0 thalassemia). If a child is not on hydroxyurea, make sure the family has talked to their hematologist about this important medication. If a child is on hydroxyurea, encourage taking it daily. You can monitor adherence by trending the mean cell volume (MCV) which increases with hydroxyurea treatment.
  6. Influenza: Immunize children with sickle cell disease against influenza every year! Influenza infection can trigger severe complications of sickle cell disease like acute chest syndrome.
  7. Sickler: Refrain from using the term “sickler.” Some people with sickle cell disease find this language offensive. Its use among ED providers has also been associated with negative attitudes toward people with sickle cell disease.4 Instead, describe a patient by their genotype as this provides important information.
  8. Genetic counseling: Make sure to educate families of children with sickle cell trait (newborn screen FAS) about the genetic inheritance of sickle cell disease. This is potentially important information for both the parents (who may both have trait and be at risk of having a child with sickle cell disease) and the child to make informed reproductive decisions.
  9. No ice: While many common musculoskeletal injuries are typically treated with ice, do not recommend the application of ice for children with sickle cell disease. Ice can trigger red cell sickling that may lead to sickle pain.
  10. Bedwetting: Nocturnal enuresis is common in children with sickle cell disease. Children with sickle cell disease have hyposthenuria (dilute urine) because sickle cell impairs the ability of the kidneys to concentrate urine. Offer support to families dealing with this problem.

Robert "Shep" Nickel, MD

References:

  1. Reeves SL, Tribble AC, Madden B, Freed GL, Dombkowski KJ. (2018) Antibiotic Prophylaxis for Children With Sickle Cell Anemia. Pediatrics.
  2. Eckrich MJ, Wang WC, Yang E, et al. (2013) Adherence to transcranial Doppler screening guidelines among children with sickle cell disease. Pediatric Blood & Cancer, 60:270-274.
  3. Reeves SL, Madden B, Freed GL, Dombkowski KJ. (2016) Transcranial Doppler Screening Among Children and Adolescents With Sickle Cell Anemia. JAMA Pediatrics, 170:550-6.
  4. Glassberg J, Tanabe P, Richardson L, Debaun M. (2013) Among emergency physicians, use of the term "Sickler" is associated with negative attitudes toward people with sickle cell disease. American Journal of Hematology, 88:532-533.

 

Legislative/Regulatory News

Sickle Cell Disease Clinical Trials

The opportunities for patients with sickle cell disease to participate in clinical research have improved significantly in the past few decades. Current research is exploring ways to reduce the risks of serious complications, including stroke, hypertension, respiratory problems, and vulnerability to overwhelming bacterial infections. It is imperative that we, as physicians, encourage patients to participate in research studies that will hopefully lead to advancements in diagnosis and treatment. There are 100 active research studies in SCD registered on www.clinicaltrials.gov as of August 22, 2018; these studies are being conducted all over the United States.

Connie M. Piccone, MD

New Therapies for Sickle Cell Disease

Development of new drugs in sickle cell disease (SCD) as well as investigation of drugs previously used in other settings have targeted cell adhesion, inflammatory pathways, upregulation of hemoglobin F, hemoglobin polymerization and sickling, coagulation, and platelet activation. Although these efforts have not yielded many drugs ready for FDA approval, several early studies have been extremely encouraging. In addition, the marked increase in clinical pharmaceutical research addressing SCD and the new and old drugs in the pipeline make it reasonable to expect that we will soon have new treatments for SCD (excerpt from Blood 2016 127:810-819).

There is one new drug that has been recently FDA approved for use in pediatric and adult patients with SCD. In July 2017, Endari (L-glutamine oral powder) was approved for patients age five years and older with SCD to reduce severe complications associated with the blood disorder. This is the first treatment approved for patients with SCD in almost 20 years! The safety and efficacy of Endari were studied in a randomized trial of patients ages 5 to 58 years old who had two or more painful crises within the 12 months prior to enrollment in the trial. Patients were assigned randomly to treatment with Endari or placebo, and the effect of treatment was evaluated over 48 weeks. Patients who were treated with Endari experienced fewer hospital visits for pain treated with a parenterally administered narcotic or ketorolac (sickle cell crises), on average, compared to patients who received a placebo (median 3 vs. median 4), fewer hospitalizations for sickle cell pain (median 2 vs. median 3), and fewer days in the hospital (median 6.5 days vs. median 11 days). Patients who received Endari also had fewer occurrences of acute chest syndrome compared with patients who received a placebo (8.6% vs. 23.1%). Common side effects of Endari include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain. Endari received Orphan Drug designation for this use, which provides incentives to assist and encourage the development of drugs for rare diseases. In addition, development of this drug was in part supported by the FDA Orphan Products Grants Program, which provides grants for clinical studies on safety and/or effectiveness of products for use in rare diseases or conditions. The study was recently published in NEJM (Niihara, Y, et al. A Phase 3 Trial of L-Glutamine in Sickle Cell Disease. NEJM 19 July 2018).

An additional drug currently being studied is Voxelotor (previously called GBT440), an oral, once-daily therapy for patients with SCD. Voxelotor works by increasing hemoglobin's affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, Global Blood Therapeutics (GBT) – the clinical-stage biopharmaceutical company developing the drug - believes voxelotor blocks polymerization and the resultant sickling of red blood cells. With the potential to improve hemolytic anemia and oxygen delivery, GBT believes that voxelotor may potentially modify the course of SCD. In recognition of the critical need for new SCD treatments, the FDA granted voxelotor Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment of patients with SCD. GBT is currently evaluating Voxelotor in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a Phase 3 clinical study in patients age 12 and older with SCD. In June of this year, GBT announced positive top-line data from Part A of the Phase 3 HOPE study. The primary endpoint was achieved with 58% of patients on Voxelotor exceeding a 1g/dL increase in hemoglobin at Week 12 of therapy compared to 9% of placebo (p<0.0001). The company met with the FDA at the end of June and is in discussions on potential accelerated approval based on the drug’s efficacy as assessed by the primary endpoint. In addition, there were numerically fewer vaso-occlusive crises (VOC) in each Voxelotor arm vs placebo.

Connie M. Piccone, MD

Celebrate Sickle Cell Awareness Month by Writing to Your Local Paper

As one way to bring awareness to sickle cell disease, individuals could engage their local paper to write an editorial or “Letter to the Editor.” If you do write a letter, some points to consider are:

  • September is designated as Sickle Cell Awareness Month
  • Sickle cell disease is an inherited chronic blood disorder which can result in chronic debilitating pain, stroke, organ damage and death
  • The disease impacts over 300,000 children born each year world-wide
  • Without newborn screening for identification and early intervention, over 50% of children afflicted will die by age 5
  • No cure for the majority of children 
  • Great need to develop uniformly effective treatments
  • Progress has been made but research breakthroughs have been few
  • It is important that these patients be managed by a team knowledgeable in treatment of sickle cell disease. Lack of such teams results in lack of access to quality care.
  • Ensure support for passage of the Sickle Cell Disease Research, Surveillance, Prevention and Treatment Act, which would increase funding for research and treatment of these patients

Eric S. Sandler, MD

ASPHO Supports Sickle Cell Bill

In July 2018, ASPHO joined the American Society of Hematology in sending a letter to Senators Lamar Alexander and Patty Murry, the Chair and Rank Member, respectively, of the Senate Health, Education, Labor, and Pensions (HELP) Committee, asking them to support S. 2465, the Sickle Cell Disease Research, Surveillance, Prevention and Treatment Act of 2018 and pass the bill out of committee and to a full Senate vote. S. 2465 would authorize a national surveillance program, which would help with a greater understanding of how many Americans are affected with sickle cell, where they live, where they receive care, and whether they have access to care. The bill also reauthorizes the existing Health Resources and Services Administration’s SCD Treatment Demonstration Program, which is important to improving patient access to the highest quality of care. The Demonstration Program continues to yield valuable results, increasing the number of SCD providers’ knowledgeable about the most effective treatments for the disease. The Senate bill passed out of the HELP Committee and is awaiting a full Senate vote. If you want to help, contact your Senators and ask them to pass this bill.

American Society of Hematology Seeks Comments on Sickle Cell Disease-Related Guidelines

The American Society of Hematology (ASH) has opened for public comment draft clinical practice guidelines on sickle cell disease-related transfusion support. More information and supporting materials may be found here. The deadline to comment is Monday, October 1, 2018.

Help Fully Fund the Childhood Cancer STAR Act

The Senate is beginning consideration of the Labor/HHS Appropriations bill that funds national health programs, including the NIH. We wanted to give you a quick update on the status of funding for the Childhood Cancer STAR Act. We need your help to reach out to members of the House Appropriations Committee Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (House LHHS Subcommittee) and ask them to fully fund the Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018 (Childhood Cancer STAR Act). The Childhood Cancer STAR Act is the most comprehensive funding bill for childhood cancer research. This bill expands opportunities for cancer research, enhances the ability to track childhood cancers, and enhances the quality of life for childhood cancer survivors. ASPHO spent many years advocating for the bill and it was finally signed into law on June 5, 2018.

However, the bill still needs to be funded. How can you help? We need constituents of the members listed here to contact their Representative on the House Labor/HHS Appropriations Subcommittee and ask them to fully fund the Childhood Cancer STAR Act.

We appreciate your continued efforts to support this bill.

For more information on our coalition partners and activities here are some helpful links:

Alliance for Childhood Cancer

American Society of Hematology

American Academy of Pediatrics

Sickle Cell Disease Coalition

Please visit our Health Policy & Advocacy website section for past issues of Advocacy Brief.

 

 

Advertising, Exhibits, & Support | Career Center | Calendar | Contact Us
Terms of Use & Privacy Policy » © The American Society of Pediatric Hematology/Oncology